Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

New agent, eribulin, derived from marine sponge, increases survival among women with metastatic breast cancer

2010 ASCO Annual Meeting

Published: 11 Jun 2010

Views: 9900

Rating:

Save

Prof Christopher Twelves - Leeds Institute of Molecular Medicine and St. James's Institute of Oncology, Leeds, UK

Prof Christopher Twelves, speaking at the 2010 ASCO conference: A Phase III randomised trial finds that a new chemotherapy agent, eribulin mesylate, extends median overall survival by 2.5 months among women with locally recurrent or metastatic breast cancer who had already been heavily treated with conventional therapies.

Click here to see Prof. Twelves speaking to ecancertv about the survival benefits of eribulin.

Related Videos

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours

Dr Jyoti Bajpai - Tata Memorial Centre, Mumbai, India

Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours ( Dr Jyoti Bajpai - Tata Memorial Centre, Mumbai, India )

Breast Cancer

Dr Nita Nair - Apollo Cancer Centres, Mumbai

Breast Cancer ( Dr Nita Nair - Apollo Cancer Centres, Mumbai )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Updates on HR-positive HER2-negative breast cancer

Dr Mariana Chavez - MD Anderson Cancer Center, Houston, USA

Updates on HR-positive HER2-negative breast cancer ( Dr Mariana Chavez - MD Anderson Cancer Center, Houston, USA )

Updates on triple-negative breast cancer and immunotherapy

Dr Avan Armaghani - Moffitt Cancer Center, Tampa, USA

Updates on triple-negative breast cancer and immunotherapy ( Dr Avan Armaghani - Moffitt Cancer Center, Tampa, USA )

More from ecancer